Expertise in
16
conditions

Dr. Carlos A. Rodriguez-Galindo

Hematology | Oncology
Office
262 Danny Thomas Pl # 515, 
Memphis, TN 
Accepting New Patients
Expertise in
16
conditions
Office
262 Danny Thomas Pl # 515, 
Memphis, TN 

Overview

Carlos Rodriguez-Galindo is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee.

Dr. Rodriguez-Galindo is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Germ Cell Tumor, Retinoblastoma, Langerhans Cell Histiocytosis, Hepatectomy, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 288 peer reviewed articles and participating in 14 clinical trials. Dr. Rodriguez-Galindo is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in TN

Languages Spoken

English
Catalan
French
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO

Locations

Office
262 Danny Thomas Pl # 515, Memphis, TN 38105

Additional Areas of Focus

Dr. Rodriguez-Galindo has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Completed
Publish Date: June 30, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate
Study Phase: Phase 3
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Enrollment Status: Completed
Publish Date: June 29, 2026
Intervention Type: Other, Procedure
Renal Tumors Classification, Biology, and Banking Study
Renal Tumors Classification, Biology, and Banking Study
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Other
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Enrollment Status: Completed
Publish Date: April 30, 2026
Intervention Type: Drug, Radiation, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Vincristine
Study Phase: Phase 3
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma
Enrollment Status: Terminated
Publish Date: April 14, 2026
Intervention Type: Other
Study Phase: Not Applicable
Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Enrollment Status: Completed
Publish Date: November 20, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With Retinoblastoma
A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With Retinoblastoma
Enrollment Status: Completed
Publish Date: October 13, 2023
Intervention Type: Drug
Study Phase: Phase 1
A COG Study for Collecting and Banking Ewing Sarcoma Specimens
A COG Study for Collecting and Banking Ewing Sarcoma Specimens
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Other
A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Other
View 9 Less Clinical Trials

288 Total Publications

Crossing Borders for Pathology Capacity Building in a Regional Setting: A Pediatric Oncology Initiative.
Crossing Borders for Pathology Capacity Building in a Regional Setting: A Pediatric Oncology Initiative.
Journal: JCO global oncology
Published: September 03, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Amar J. Gajjar
Hematology | Oncology
Expertise in
18
conditions
Dr. Amar J. Gajjar
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (0.2 miles away)
901-595-2615
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amar Gajjar is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Gajjar is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Posterior Fossa Tumor, Brain Tumor, Embryonal Tumor with Multilayered Rosettes, and Posterior Fossa Decompression. Dr. Gajjar is currently accepting new patients.

Expertise in
13
conditions
Dr. Giles W. Robinson
Hematology | Oncology
Expertise in
13
conditions
Dr. Giles W. Robinson
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (0.2 miles away)
901-595-5175
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Giles Robinson is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Robinson is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Posterior Fossa Tumor, and Rhabdoid Tumor. Dr. Robinson is currently accepting new patients.

Expertise in
7
conditions
Dr. Jane S. Hankins
Hematology | Oncology
Expertise in
7
conditions
Dr. Jane S. Hankins
Hematology | Oncology
Referral may be required

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (0.2 miles away)
901-595-4153
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jane Hankins is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Hankins is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Splenectomy, and Adenoidectomy. Dr. Hankins is currently accepting new patients.

Frequently Asked Questions about Dr. Carlos A. Rodriguez-Galindo

How do I make an appointment with Dr. Carlos A. Rodriguez-Galindo?

You can book an appointment with Dr. Carlos A. Rodriguez-Galindo by calling their office at 901-595-3300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Carlos A. Rodriguez-Galindo a top-rated expert for Germ Cell Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Carlos A. Rodriguez-Galindo is classified as an Elite expert for Germ Cell Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Carlos A. Rodriguez-Galindo specialize in?

While Dr. Carlos A. Rodriguez-Galindo is a Hematology, they have specific expertise in Germ Cell Tumor, Retinoblastoma, and Langerhans Cell Histiocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Carlos A. Rodriguez-Galindo participate in research or clinical trials?

Yes. Dr. Carlos A. Rodriguez-Galindo has published 288 articles and abstracts on conditions like Germ Cell Tumor. You can view a list of Dr. Carlos A. Rodriguez-Galindo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Carlos A. Rodriguez-Galindo accept my insurance?

Dr. Carlos A. Rodriguez-Galindo accepts most major insurance plans, including Blue Cross Blue Shield. We recommend calling the office directly at 901-595-3300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rodriguez-Galindo's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile